Imfinzi Injection

Introduction

Imfinzi is a prescription medication that contains the active ingredient Durvalumab. It is available under the brand name Imfinzi. This medication is primarily used for the treatment of certain types of cancer.

Uses

Imfinzi is prescribed to patients with specific types of cancer, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and urothelial carcinoma. It is used as a type of immunotherapy, which helps the body’s immune system fight cancer cells.

Dosage and Administration

The dosage and administration of Imfinzi may vary depending on the specific type of cancer being treated and the patient’s individual condition. It is typically administered by a healthcare professional through an intravenous infusion.

The recommended dose and schedule for Imfinzi will be determined by your healthcare provider. Follow their instructions carefully and not to change the dosage or administration without consulting them.

Mechanism of Action

Imfinzi works by targeting a protein called PD-L1, which is found on some cancer cells and immune cells. By blocking the interaction between PD-L1 and another protein called PD-1, this medication helps activate the immune system to recognize and attack cancer cells.

Side Effects

Common side effects may include fatigue, nausea, diarrhea, decreased appetite, and rash. These side effects are usually mild to moderate and may improve over time.

However, some patients may experience more serious side effects. These can include severe allergic reactions, lung problems, liver problems, kidney problems, and hormonal imbalances. If you experience any of these side effects or have concerns, contact your healthcare provider immediately.

Drug Interactions

Imfinzi may interact with certain medications. Inform your healthcare provider about all the medications you are taking, including prescription, over-the-counter, and herbal products. They can help determine if any potential drug interactions may occur and adjust your treatment plan accordingly.

Precautions

Before starting treatment with Imfinzi, inform your healthcare provider about any medical conditions you have, including allergies, autoimmune disorders, liver or kidney problems, and lung diseases. Imfinzi may not be suitable for all patients.

Avoid vaccinations with live vaccines while receiving treatment with Imfinzi, as it may interfere with their effectiveness. Additionally, inform your healthcare provider about any other medications you are taking to avoid potential interactions.

Storage

Imfinzi should be stored in a refrigerator at a temperature between 2°C and 8°C (36°F and 46°F). Do not freeze the medication. Keep it in the original packaging and protect it from light. Do not use Imfinzi if it has been frozen or if the expiration date has passed.

Patient Tips

• Follow your healthcare provider’s instructions regarding the schedule and dosage of Imfinzi.
• Be aware of the potential side effects and contact your healthcare provider if you experience any concerning symptoms.
• Keep a record of any side effects or changes in your condition to discuss with your healthcare provider during follow-up appointments.
• Inform your healthcare provider about any other medications you are taking, including over-the-counter and herbal products.
• Store Imfinzi properly in the refrigerator to maintain its effectiveness.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Durvalumab (Drugs.com) [Accessed 1 Jun. 2024] (online) Available at:
• durvalumab solution (RX) [Accessed 12 Jun. 2024] (online) Available at:
• Durvalumab Injection (MedlinePlus) [Accessed 25 Jun. 2024] (online) Available at:
• Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Shi X, Poole L, Peters S, Garon EB, Mok T; POSEIDON investigators. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study. J Clin Oncol. 2023 Feb 20;41(6):1213-1227. doi: 10.1200/JCO.22.00975. Epub 2022 Nov 3. [Accessed 26 Jun. 2024] Available at: